Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model

Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to correlate mast cells to decreased engraftment time and increased overall myeloma engraftment. Mast cells may also correlate to worsened bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our findings demonstrate the utility of the NSG hIL6 model for studying human bone marrow–myeloma crosstalk, including mast cells.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-10-16
DOI
https://doi.org/10.1038/s41598-026-75919-w
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model

Sandra P. Susanibar-Adaniya, Adam D. Cohen, Adam Justin Waxman, Edward Allen Stadtmauer et al.
Scientific Reports
Multiple Myeloma Research and Treatments
article

Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model

Sandra P. Susanibar-Adaniya, Adam D. Cohen, Adam Justin Waxman, Edward Allen Stadtmauer, Alfred L. Garfall, Zainul S. Hasanali, Dan T. Vogl, Shivani Kapur, Cara A. Cipriano, David Allman, Kristy Weber
article en

Abstract

Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to correlate mast cells to decreased engraftment time and increased overall myeloma engraftment. Mast cells may also correlate to worsened bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our findings demonstrate the utility of the NSG hIL6 model for studying human bone marrow–myeloma crosstalk, including mast cells.

Scientific Reports
Indiana University Health (US), Walther Cancer Foundation (US), Indiana University – Purdue University Indianapolis (US), University of Pennsylvania (US)
University of Pennsylvania, Mark Foundation For Cancer Research, Georgia Clinical and Translational Science Alliance, National Center for Advancing Translational Sciences
Good health and well-being
Openalex Percentile: Top 13%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.